4-苯基烟腈 | 39065-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-苯基烟腈
• 英文名称: 3-cyano-4-phenylpyridine
• 英文别名: 4-phenylnicotinonitrile；4-phenylpyridine-3-carbonitrile
• CAS: 39065-51-5
• 化学式: C₁₂H₈N₂
• 分子量: 180.209
• InChiKey: ACKSTMUOXBUQHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  347.4±30.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-苯基烟腈 在 PPA 、 Polyphosphoric acid (PPA) 作用下， 反应 10.0h， 以85%的产率得到(3-(甲基氨基)-5-苯基噻吩-2-基)(苯基)甲酮
  参考文献：
  名称：

  Syntheses of 2-Azafluorenones from 3-Substituted 4-Arylpyridines

  摘要：

  3-Substituted 4-arylpyridines (5a-i) were synthesized in good yields by reaction of mixed copper, zinc aryl organometallics (2a-e) with 1-ethoxycarbonyl-pyridinium chlorides (1a-d) followed by o-chloranil oxidation under reflux in toluene. The 4-arylpyridines (5a-i) are obtained predominantly. Having compounds (5a-i) in hand, a convenient method was developed for the synthesis of 2-azafluorenones (7a-f) by using cyclization of 4-arylpyridines (5a-i) with polyphosphoric acid.

  DOI：

  10.3987/com-92-6199
• 作为产物：
  描述：

  3-cyano-1,4-dihydro-1-(dimethylthexylsilyloxy)methyl-4-phenylpyridine 在 四丁基氟化铵 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 15.0h， 生成 4-苯基烟腈
  参考文献：
  名称：

  芳基和炔基三异丙氧基钛试剂在嗪的区域选择性碳-碳键形成中的作用

  摘要：

  吡啶的4位区域选择性芳基化是由DDQ连续脱氢和1位取代基裂解后，芳基三异丙氧基钛试剂与N-异丁氧基羰基-或N-甲硅烷氧基甲基-3-氰基吡啶鎓盐之间的1：1加合物形成而引起的。在4位上形成新的C bondC键的完全区域选择性导致芳基和苯基乙炔基三异丙氧基钛试剂与嘧啶2（1 H）-酮之间形成加合物。乙炔基三异丙氧基钛与新的CC键形成在6位上。

  DOI：

  10.1016/0040-4020(92)80015-8

文献信息

• Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
  申请人：Mallams K. Alan

  公开号：US20070066621A1

  公开（公告）日：2007-03-22

  In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种形式中，本发明提供了一类新颖的吡唑并[1,5-a]吡啶，吡唑并[1,5-c]嘧啶和2H-吲唑化合物的4-氰基，4-氨基和4-氨基甲基衍生物，以及咪唑并[1,2-a]吡啶和咪唑并[1,5-a]吡嗪化合物的5-氰基，5-氨基和5-氨基甲基衍生物作为细胞周期依赖性激酶的抑制剂，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备包含一种或多种此类化合物的药物制剂的方法，以及使用此类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
• [EN] IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] DERIVES D'IMIDAZO-PYRIMIDINE COMME LIGANDS POUR LES RECEPTEURS GABA
  申请人：MERCK SHARP & DOHME

  公开号：WO2002074773A1

  公开（公告）日：2002-09-26

  A class of 3-phenylimidazo[1,2-a]pyrimidine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a -NH- linkage, and further substituted on the phenyl ring by alkyl, trifluoromethyl, alkoxy or one or two halogen atoms, especially fluoro, are selective ligands for GABAA receptors, in particular having good affinity for the a2 and/or a3 and/or a5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

  一类3-苯基咪唑并[1,2-a]嘧啶衍生物，苯环的间位被取代为可选择取代的芳基或杂环基，该基团直接连接或通过氧原子或-NH-键桥接，并且苯环上进一步取代为烷基，三氟甲基，烷氧基或一个或两个卤素原子，特别是氟原子。这些化合物是GABAA受体的选择性配体，特别是对其中的a2和/或a3和/或a5亚基具有良好的亲和力，因此有助于治疗和/或预防中枢神经系统的不良症状，包括焦虑，抽搐和认知障碍。
• 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
  申请人：——

  公开号：US20040267017A1

  公开（公告）日：2004-12-30

  The invention provides novel thiazoles bearing 3-pyridyl or 4-isoquinilinyl substituents, and pharmaceutical compositions thereof. The invention also provides methods of using compounds of the invention and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17a-hydroxylase-C17,20 enzyme. The invention further provides methods for treating cancer in a subject, comprising administering to the subject a compound of the invention or a pharmaceutical composition thereof. The cancer can be, e.g., prostate cancer or breast cancer.

  本发明提供了一种带有3-吡啶基或4-异喹啉基取代基的新型噻唑，并提供了其制药组合物。本发明还提供了使用本发明化合物和制药组合物作为裂解酶抑制剂（例如17a-羟基酶-C17,20酶）的方法。本发明还提供了治疗患者癌症的方法，包括向患者投药本发明化合物或制药组合物。癌症可以是前列腺癌或乳腺癌等。
• NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS
  申请人：Mallams Alan K.

  公开号：US20100137326A1

  公开（公告）日：2010-06-03

  In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的4-氰基、4-氨基和4-氨甲基吡唑并[1,5-a]吡啶、吡唑并[1,5-c]嘧啶和2H-吲哚化合物以及5-氰基、5-氨基和5-氨甲基咪唑并[1,2-a]吡啶和咪唑并[1,5-a]吡嗪化合物，作为细胞周期蛋白依赖性激酶的抑制剂，制备这种化合物的方法，含有一种或多种这种化合物的制药组合物，制备包含一种或多种这种化合物的制药配方的方法，以及使用这种化合物或制药组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
• Indole-substituted 3-cyanopyridines As Kinase Inhibitors
  申请人：Boschelli Diane Harris

  公开号：US20110028455A1

  公开（公告）日：2011-02-03

  Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X is —O—, —N(R 3 )—, —S—, —S(O)— or —S(O) 2 —; R 2 is a C 1-4 alkyl group or —CF 3 ; and R 1 , R 3 , R 4 and p are as defined herein; wherein the compounds are useful as kinase inhibitors. Also disclosed are pharmaceutical compositions containing, and intermediate compounds and methods for making the compounds of formula (I) and their pharmaceutically acceptable salts; and methods of using the foregoing to treat inflammatory and autoimmune diseases such as asthma, colitis, multiple sclerosis, psoriasis, arthritis, rheumatoid arthritis, inflammatory bowel disease, and joint inflammation.

  本发明公开了式（I）化合物及其药学上可接受的盐，其中X为—O—、—N（R3）—、—S—、—S（O）—或—S（O）2—；R2为C1-4烷基或—CF3；R1、R3、R4和p如本文所定义；所述化合物可用作激酶抑制剂。还公开了含有上述化合物的制药组合物，以及制备式（I）化合物及其药学上可接受的盐的中间体化合物和方法；以及使用上述化合物治疗炎症和自身免疫性疾病，如哮喘、结肠炎、多发性硬化症、牛皮癣、关节炎、类风湿性关节炎、炎症性肠病和关节炎的方法。

表征谱图